In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck licenses NK-1 antagonist VPD737 to Tigercat Pharma

Executive Summary

Virtual biotech start-up Tigercat Pharma Inc. received exclusive worldwide rights to Merck & Co. Inc.’s Phase II serlopitant (VPD737) for chronic pruritis (itching that lasts for more than six weeks).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Reverse Licensing
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies